Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
26.03. | Medicenna Therapeutics Corp: Medicenna to present MDNA11 update at AACR | 1 | Stockwatch | ||
26.03. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
25.02. | Medicenna Therapeutics Corp: Medicenna talks MDNA11 Ability-1 study data | 1 | Stockwatch | ||
13.02. | Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | 122 | GlobeNewswire (Europe) | - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1... ► Artikel lesen | |
05.02. | Stocks in Play: Medicenna Therapeutics Corp | - | Baystreet.ca | ||
13.12.24 | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS) | 1 | GlobeNewswire (USA) | ||
05.12.24 | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
05.12.24 | Medicenna Therapeutics Corp.: Medicenna Provides Clinical Update and Announces First Complete Response in MDNA11 in Combination with KEYTRUDA (pembrolizumab) Dose Escalation Arm of the ABILITY-1 Study | 132 | GlobeNewswire (Europe) | 70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck's (known as MSD outside of the US and Canada)... ► Artikel lesen | |
27.11.24 | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
27.11.24 | Medicenna to present updated ABILITY-1 study data | - | Investing.com | ||
25.11.24 | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) | 1 | GlobeNewswire (USA) | ||
15.11.24 | Medicenna Therapeutics GAAP EPS of -C$0.05 | 2 | Seeking Alpha | ||
15.11.24 | Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update | 164 | GlobeNewswire (Europe) | MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression... ► Artikel lesen | |
13.11.24 | Medicenna Therapeutics Corp.: Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS) | 3 | GlobeNewswire (USA) | ||
11.11.24 | Medicenna Therapeutics Corp: Medicenna talks MDNA11 Ability-1 study results | 2 | Stockwatch | ||
11.11.24 | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
11.11.24 | Medicenna Therapeutics Corp.: Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA (pembrolizumab) at the ... | 136 | GlobeNewswire (Europe) | Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with... ► Artikel lesen | |
08.11.24 | Medicenna Therapeutics Corp.: Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | 185 | GlobeNewswire (Europe) | MDNA113 is a novel IL-13Ra2 tumor-targeted and "masked" BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor microenvironment... ► Artikel lesen | |
15.10.24 | OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX | 125 | GlobeNewswire (Europe) | NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna Therapeutics... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,320 | +1,41 % | EQS-News: Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024 | EQS-News: Evotec SE
/ Schlagwort(e): Jahresbericht
Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
17.04.2025... ► Artikel lesen | |
TEMPUS AI | 51,04 | +2,97 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
QIAGEN | 37,485 | -0,16 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
BIONTECH | 102,70 | +1,28 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 13,530 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) | ||
TARSUS PHARMACEUTICALS | 49,990 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | ||
NURIX THERAPEUTICS | 11,640 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions | Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical... ► Artikel lesen | |
CG ONCOLOGY | 20,720 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
ADMA BIOLOGICS | 22,200 | +2,07 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
BICARA THERAPEUTICS | 15,480 | 0,00 % | Bicara wird aktualisierte Studiendaten auf ASCO-Tagung präsentieren | ||
HARMONY BIOSCIENCES | 28,910 | 0,00 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
RECURSION PHARMACEUTICALS | 5,660 | +1,62 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
PRAXIS PRECISION MEDICINES | 36,590 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 39,600 | 0,00 % | MoonLake sichert sich Finanzierung von Hercules Capital in Höhe von bis zu 500 Millionen Dollar | Zug - MoonLake Immunotherapeutics, ein in der klinischen Phase befindliches Biotechnologieunternehmen, das sich auf die Entwicklung von neuartigen Therapien für Entzündungskrankheiten konzentriert,... ► Artikel lesen | |
BB BIOTECH | 29,900 | -0,50 % | BB Biotech Aktie: Vor Quartalszahlen unter Druck | BB Biotech verzeichnet deutliche Kursverluste, doch Analysten halten an positiven Erwartungen fest. Die anstehenden Quartalszahlen könnten neue Impulse bringen. Die BB Biotech-Aktie zeigt sich vor der... ► Artikel lesen |